Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 12 March 2012
A lawsuit filed by an Idaho woman claims negligence on the part of Genzyme, now a subsidiary of Sanofi, led to persistent drug shortages and consequently the death of her husband.
Shortages of Fabrazyme, used to treat Fabry Disease, started in 2009 when viral contamination was discovered at a Genzyme manufacturing facility. Shortages were further exacerbated when additional contamination was found by the US Food and Drug Administration later in 2009, leading to a situation in which the drug was rationed out to patients.
The lawsuit claims the suboptimal dose was insufficient to maintain her husband's health, and that Genzyme knew "many patients would suffer catastrophic health deterioration and even death."
The lawsuit further claims that Genzyme's quality problems constitute "negligence" and the shortages were carried out in pursuit of a "profit motive."
Pharmalot - Fabrazyme Shortage Killed My Husband: Widow
Lawsuit - Janet Schubert vs. Genzyme; Sanofi
Tags: Death, Idaho, Fabrazyme, Fabrys Disease, Genzyme, Lawsuit, Shortages, Sanofi, Latest News
Regulatory Focus newsletters
All the biggest regulatory news and happenings.